Agios to Present at March Investor Conferences
Get Alerts AGIO Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the following March investor conferences:
- Cowen 41st Annual Virtual Healthcare Conference on Monday, March 1, 2021 at 11:40 a.m. ET; and
- Oppenheimer 31st Annual Virtual Healthcare Conference on Wednesday, March 17, 2021 at 9:20 a.m. ET.
Live webcasts of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.
About AgiosAgios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.
Contacts
Investors & Media:Holly Manning, 617-844-6630Director, Investor Relations[email protected]
Source: Agios Pharmaceuticals, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Adora Mediterranea Kicks Off 2026 Tianjin Sailing Season
- RedCloud Signs Up to $120M India Joint Venture, to Deploy Its RAID Engine Into FMCG, Apparel and Footwear Categories
- InvestorNewsBreaks – Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Reports 59% Increase in Measured and Indicated Resources at Gaocheng Mine
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share